Ozempic vs Wegovy for Teens

Ozempic and Wegovy contain the same medicine, semaglutide, but they are approved for different things. Wegovy is FDA-approved for weight management in patients 12 and older. Ozempic is approved only for adults with type 2 diabetes and has no pediatric approval for any use. Prescribing Ozempic to a teenager is off-label.

Parents almost always arrive at this question through Ozempic, because that is the name that ended up in the news. Then a clinician mentions Wegovy, and the natural reaction is to wonder whether someone is steering the family toward a different drug for a reason that has nothing to do with the child.

They are the same molecule. The difference is what the FDA reviewed, in whom, and at what dose. That difference is not a technicality, and it is worth understanding before any decision gets made.

Are Ozempic and Wegovy the same drug?

Yes, chemically. Both are semaglutide, a GLP-1 receptor agonist given as a weekly injection. GLP-1 is a hormone your gut releases after eating. It slows stomach emptying, signals fullness to the brain, and helps the pancreas release insulin appropriately.

Novo Nordisk markets the same molecule under two names because it was studied and approved for two different purposes, in two different populations, at two different maximum doses.

The Ozempic prescribing information states plainly that safety and effectiveness have not been established in pediatric patients. That sentence is the whole answer to the first question most parents ask.

Can a teenager take Ozempic?

Not on-label. Every use of Ozempic in someone under 18 is off-label, whether it is prescribed for weight or for diabetes.

Off-label prescribing is legal, and it is genuinely common in pediatrics — many excellent medications for children were never formally studied in children. It is not automatically wrong. But it does mean the FDA never reviewed that specific use, and here it is unnecessary, because a version of the exact same molecule was studied in adolescents and was approved for them.

When there is an on-label option with pediatric trial data behind it, reaching past it for the off-label one requires a specific clinical reason. Insurance coverage is also harder to obtain off-label, and the prescriber assumes more liability.

Is Wegovy approved for teens?

Yes. In December 2022 the FDA approved Wegovy for chronic weight management in patients aged 12 and older with an initial BMI at or above the 95th percentile for age and sex, used alongside a reduced-calorie eating plan and increased physical activity.

The approval followed the STEP TEENS trial, published in the New England Journal of Medicine, which enrolled 201 adolescents aged 12 to 17. All participants completed a lifestyle phase before being randomized to weekly semaglutide or placebo for 68 weeks. Mean BMI fell 16.1% in the semaglutide group and rose slightly with placebo. Waist circumference, ALT, A1c, and lipids improved more in the treatment group.

Two things in that description deserve emphasis, because they get dropped in most coverage. The approval is anchored to a BMI percentile, not the fixed number used for adults. And the medication was studied as an addition to lifestyle treatment, not as a replacement for it.

Can a 10-year-old take Wegovy?

No. Wegovy is not approved for children under 12, and prescribing it below that age would be off-label.

The reason is not bureaucratic. There is no completed efficacy trial of weekly semaglutide in children under 12, which means no validated dose, no published pediatric pharmacokinetic curve for that age group, and no regulatory review of the risk-benefit balance. As of this writing, no anti-obesity medication carries FDA approval for children under 12.

There is also a growth question specific to this age group that does not apply to adults. These medications work partly by reducing appetite and calorie intake. A prepubertal child is still building height. Sustained caloric restriction during that window carries a theoretical risk to linear growth that has not been studied in this population, and "not studied" is not the same as "shown to be safe."

For children aged 6 to 11, the American Academy of Pediatrics recommends intensive health behavior and lifestyle treatment as the primary approach. Done properly, that means substantial family-based contact hours, not a printed handout and a follow-up in a year.

That is the honest answer, and it is frequently not the answer a worried parent of a 10-year-old is hoping for. It is still the right one. There is real work to do for a child that age, and it starts with finding out why the weight is climbing — which is a different question from what to prescribe.

What else is approved for adolescents

Semaglutide is not the only option, and it is not automatically the right first one.

• Saxenda (liraglutide) — approved for adolescents 12 to 17 with obesity. Daily injection rather than weekly.
• Orlistat — approved from age 12. Works in the gut rather than on appetite. Different side-effect profile.
• Metformin — not an approved obesity medication, but frequently appropriate where insulin resistance is the driver.
• Tirzepatide — carries a pediatric indication from age 10 for type 2 diabetes under the brand Mounjaro. Zepbound, the weight-management brand, remains adult-only. The adolescent obesity trial has not yet produced an approval.

Which of these fits depends on the specific child. A teenager with insulin resistance and a family history of type 2 diabetes is a different case from a teenager whose weight climbed after a medication change, which is different again from a teenager whose growth chart shows weight rising while height stalls. That last pattern in particular points toward an endocrine cause and is worth its own evaluation.

What a pediatric endocrinologist evaluates before prescribing

The medication conversation is not the first conversation. It is usually the fourth or fifth.

The full growth history. For a metabolic evaluation at LIFE, we ask for both the first five years and the last five years of height and weight data. Early childhood weight patterns matter enormously here — rapid weight gain before age five points somewhere very different than weight gain that began at eleven. A single BMI reading tells us almost nothing. A twelve-year trajectory tells us most of what we need to know.

Whether something else is driving it. Thyroid function. Cortisol excess. Insulin resistance and PMOS. Medication effects, particularly from atypical antipsychotics, some antiseizure medications, and steroids. Genetic causes of obesity, which are more common than most families are told and which change the treatment plan entirely when found.

What eating and daily life actually look like. Not a lecture. An accurate picture. Sleep, screen timing, meal structure, who cooks, what the schedule allows, whether the household has one set of rules or three.

Whether there are weight-related complications already present. Fatty liver, blood pressure, lipids, A1c, sleep apnea, joint pain, irregular periods.

What the family actually wants. A teenager who is being bullied has a different goal from a teenager with a rising A1c, whose goal differs again from a parent worried about a family history. Treating to the family's goals rather than to a number is the part most easily skipped.

Only after that does the question of whether a medication belongs in the plan — and if so, which one — have a real answer.

A note on compounded semaglutide

Compounded semaglutide is not Wegovy. It is not FDA-approved, has no pediatric approval, and has not been evaluated for consistency of dose or purity in children. The price is lower for a reason. For an adolescent, this is not a place to economize.

When to see a pediatric endocrinologist

• Weight has climbed steadily across percentile lines rather than tracking along one
• Weight is rising while height growth has slowed
• There are signs of insulin resistance, such as darkened velvety skin at the neck or armpits
• Periods are irregular or absent alongside weight gain
• A first-degree relative has type 2 diabetes
• Rapid weight gain began before age five
• A medication has been suggested and you want a specialist's assessment before starting
• Lifestyle change has been sustained and genuine, and it has not worked

Coverage is a separate hurdle from candidacy, and it has its own rules. We walk through what plans typically require in does insurance cover Wegovy for teens.

Frequently asked questions

Can kids take Ozempic?

No, not on-label. Ozempic is FDA-approved only for adults with type 2 diabetes, and its labeling states that safety and effectiveness have not been established in pediatric patients. Any use in someone under 18 is off-label. When a GLP-1 is appropriate for an adolescent, the FDA-approved option is Wegovy, which contains the same medicine.

Is Wegovy approved for teens?

Yes. The FDA approved Wegovy in December 2022 for chronic weight management in patients aged 12 and older with an initial BMI at or above the 95th percentile for age and sex. It is approved as an addition to a reduced-calorie eating plan and increased physical activity, not as a replacement for them.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide, the same active medicine. Ozempic is approved for type 2 diabetes in adults, with a maximum dose of 2 mg weekly. Wegovy is approved for chronic weight management from age 12, with a maximum dose of 2.4 mg weekly. The molecule is identical; the approved use, approved ages, and dosing differ.

Can a 10-year-old take Wegovy?

No. Wegovy is approved from age 12, so use in a 10-year-old would be off-label. No efficacy trial of weekly semaglutide has been completed in children under 12, and no anti-obesity medication currently holds FDA approval for that age group. The American Academy of Pediatrics recommends intensive lifestyle treatment for children aged 6 to 11.

Medically reviewed by

Natalie Hernandez, MD — Pediatric endocrinologist at LIFE Pediatric Endocrinology and lead physician for metabolic and obesity medicine. Board certified in Pediatrics; board eligible in Pediatric Endocrinology. Dr. Hernandez completed her pediatric endocrinology fellowship at Duke University Hospital, where her research focused on metabolomics and insulin resistance in youth-onset type 2 diabetes. Her work has been published in the Journal of Clinical Endocrinology & Metabolism. Read Dr. Hernandez's full profile →

Talk with a pediatric endocrinologist

Families are never required to enroll in a program to be seen. You can come in for a metabolic evaluation, a second opinion on a medication that has already been suggested, or simply to understand what is driving the pattern on your child's growth chart.

LIFE Pediatric Endocrinology sees families nationwide by telemedicine, and in person at our offices in Austin, Sandy Springs, Beverly Hills, Newport Beach, and Brentwood. Request a consultation →

Medical disclaimer

This article is for general educational purposes and does not constitute medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a qualified healthcare professional, and reading it does not create a physician-patient relationship. Every child is different. Do not start, stop, or change any medication based on this article. Talk with your child's pediatrician or a pediatric endocrinologist about your child's specific situation. If your child has a medical emergency, call 911 or go to the nearest emergency department.

Sources

• U.S. Food and Drug Administration — Wegovy (semaglutide) prescribing information
• U.S. Food and Drug Administration — Ozempic (semaglutide) prescribing information
• Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–2257.
• Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023.
• Pediatric Endocrine Society — Drugs and Therapeutics Committee updates